AILSI, an artificial intelligence (AI) BioTech company that originated in Mainland China and Japan, is now headquartered in Hong Kong. The company leverages in-house-developed AI models to identify new disease targets based on human omics data and then design molecules for the specific target. AILSI’s AI models have all been validated by accredited third-party laboratories.
AILSI's founding team comes from top universities, renowned research labs, and the research and development departments of leading multinational pharmaceutical companies, with over 20 years of hands-on experience in drug discovery, disease biology, bioinformatics, computational chemistry, AI model design, and medicinal chemistry.
AILSI possesses strong domain knowledge and expertise in AI and drug discovery. With each team member contributing from different fields and perspectives, the company distinguishes itself in both depth and breadth compared to competitors. Additionally, the company has established valuable connections with several multinational pharmaceutical companies, leading BioTech companies, renowned research institutions, and hospitals.
